person · Reporting owner

HUGIN ROBERT J

Disclosed activity across 7 companies

Tapewire entity: 16186
SEC CIK: 0001232505

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Biohaven Ltd.BHVN · Entity 4379	Director	April 28, 2026	May 01, 2026
Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269	Director	October 03, 2022	October 03, 2022
CELGENE CORP /DE/CELG · Entity 15781	Director · see remarks	December 31, 2017	January 31, 2018
Chubb LtdCB · Entity 1639	Director	May 21, 2026	May 26, 2026
DANAHER CORP /DE/DHR · Entity 2871	Director	May 15, 2017	May 17, 2017
MEDICINES CO /DEMDCO · Entity 152552	Director	November 09, 2017	November 13, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Biohaven Ltd.

Report date April 28, 2026 · Filed May 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28	Direct	68,693	Reported balance After 2026-04-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Biohaven Pharmaceutical Holding Co Ltd.

Report date October 03, 2022 · Filed October 03, 2022

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2022-10-03 transaction · row 1 1 source row Row 1 · 2022-10-03 · Disposition to issuer · Disposed 2,900 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
Restricted Share Unit AwardSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-03 · Disposition to issuer · Disposed 3,417 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28	Direct	Reported balance After 2022-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05	Direct	Reported balance After 2022-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.88 · Expires 2030-06-09	Direct	Reported balance After 2022-10-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-03 · Disposition to issuer · Disposed 18,948 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").

F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

CELGENE CORP /DE/

Report date December 31, 2017 · Filed January 31, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,015,106	Reported balance After 2017-09-07 transaction · row 1 1 source row Row 1 · 2017-09-07 · Gift · Disposed 45,000 · Balance 1,015,106 F1: Gift to a family foundation of which Mr. Hugin is a trustee, but he is not deemed to hold a pecuniary interest in the foundation.
Common StockSEC Table I · non-derivative	IndirectBy Children	9,600	Reported balance Holding disclosure · report date 2017-12-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 9,600 F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	Indirect401(k) Plan	641	Reported balance Holding disclosure · report date 2017-12-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 641

Filing footnotes · ownership attribution and instrument terms

F1: Gift to a family foundation of which Mr. Hugin is a trustee, but he is not deemed to hold a pecuniary interest in the foundation.

F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Chubb Ltd

Report date May 21, 2026 · Filed May 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	21,626	Reported balance After 2026-05-21 transaction · row 1 1 source row Row 1 · 2026-05-21 · Grant · Acquired 1,135 · Balance 21,626 F1: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.
Common SharesSEC Table I · non-derivative	IndirectBy Son	225	Reported balance Holding disclosure · report date 2026-05-21 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 225 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
Common SharesSEC Table I · non-derivative	IndirectBy Son	110	Reported balance Holding disclosure · report date 2026-05-21 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 110 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.

F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

DANAHER CORP /DE/

Report date May 15, 2017 · Filed May 17, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,576	Reported balance After 2017-05-15 transaction · row 1 1 source row Row 1 · 2017-05-15 · Grant · Acquired 990 · Balance 3,576 F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date, or the date of (and immediately prior to) the next annual meeting of Danaher's shareholders following the grant date, but the underlying shares are not issued until the earlier of the director's death or the first day of the seventh month following the director's retirement from the Board.
Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.28 · Expires 2027-05-15	Direct	3,540	Reported balance After 2017-05-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-05-15 · Grant · Acquired 3,540 · Balance 3,540

Filing footnotes · ownership attribution and instrument terms

F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date, or the date of (and immediately prior to) the next annual meeting of Danaher's shareholders following the grant date, but the underlying shares are not issued until the earlier of the director's death or the first day of the seventh month following the director's retirement from the Board.

MEDICINES CO /DE

Report date November 09, 2017 · Filed November 13, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	163,431	Ending reported balance After 2017-11-09 transaction · row 5 5 source rows · reconciled sequence Row 1 · 2017-11-09 · Exercise / conversion · Acquired 7,500 · Balance 123,133 Row 2 · 2017-11-09 · Exercise / conversion · Acquired 7,500 · Balance 130,633 Row 3 · 2017-11-09 · Exercise / conversion · Acquired 7,500 · Balance 138,133 Row 4 · 2017-11-09 · Exercise / conversion · Acquired 13,259 · Balance 151,392 Row 5 · 2017-11-09 · Exercise / conversion · Acquired 12,039 · Balance 163,431
Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.30 · Expires 2018-05-29	Direct	0	Reported balance After 2017-11-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-11-09 · Exercise / conversion · Disposed 7,500 · Balance 0 F6: Not applicable F1: This option vested in twelve equal monthly installments beginning on June 29, 2008.
Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2019-05-28	Direct	0	Reported balance After 2017-11-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-11-09 · Exercise / conversion · Disposed 7,500 · Balance 0 F6: Not applicable F2: This option vested in twelve equal monthly installments beginning on June 28, 2009.
Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2020-06-02	Direct	0	Reported balance After 2017-11-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-11-09 · Exercise / conversion · Disposed 7,500 · Balance 0 F6: Not applicable F3: This option vested in twelve equal monthly installments beginning on July 2, 2010.
Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.18 · Expires 2021-05-26	Direct	0	Reported balance After 2017-11-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-11-09 · Exercise / conversion · Disposed 13,259 · Balance 0 F6: Not applicable F4: This option vested in one installment beginning on June 26, 2011.
Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.14 · Expires 2022-05-22	Direct	0	Reported balance After 2017-11-09 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-11-09 · Exercise / conversion · Disposed 12,039 · Balance 0 F6: Not applicable F5: This option vested in one installment beginning on June 22, 2012.

Filing footnotes · ownership attribution and instrument terms

F1: This option vested in twelve equal monthly installments beginning on June 29, 2008.

F2: This option vested in twelve equal monthly installments beginning on June 28, 2009.

F3: This option vested in twelve equal monthly installments beginning on July 2, 2010.

F4: This option vested in one installment beginning on June 26, 2011.

F5: This option vested in one installment beginning on June 22, 2012.

F6: Not applicable

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Allergan plc

Report date May 08, 2020 · Filed May 12, 2020

Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value $0.0001SEC Table I · non-derivative	Direct	0	Reported balance After 2020-05-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-05-08 · Disposition to issuer · Disposed 4,294 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 30, 2017 Filed Oct 31, 2017 21:24 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	27,444	Not disclosed Strike: $100.97	Not disclosed	Disclosure SEC source: 0001209191-17-058526 · doc4.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,444 Underlying: Common Stock · 27,444 shares Expires 2027-10-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments, commencing on October 30, 2018. F2 · ownership.direct: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. Read SEC document
October 26, 2017 Filed Oct 26, 2017 16:44 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionStock Option · Derivative	2,020	Not disclosed Strike: $49.48	Not disclosed	Disclosure SEC source: 0001209191-17-058029 · doc4.xml · derivative · entry 6 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,020 shares Expires 2023-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly the 2008 Stock Incentive Plan). F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document
October 26, 2017 Filed Oct 26, 2017 16:44 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionStock Option · Derivative	60,000	Not disclosed Strike: $31.21	Not disclosed	Disclosure SEC source: 0001209191-17-058029 · doc4.xml · derivative · entry 5 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2018-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The option was issued pursuant to the Company's 1998 Employee Stock Option Plan. F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document
October 26, 2017 Filed Oct 26, 2017 16:44 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	2,020	$49.48	$99,949.60	Disclosure SEC source: 0001209191-17-058029 · doc4.xml · nonDerivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,060,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 26, 2017 Filed Oct 26, 2017 16:44 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	60,000	$31.21	$1,872,600.00	Disclosure SEC source: 0001209191-17-058029 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 07, 2017 Filed Jan 31, 2018 16:39 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GiftCommon Stock	45,000	$0.00	$0.00	Disclosure SEC source: 0001209191-18-006228 · doc5.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,015,106 F1 · kind: Gift to a family foundation of which Mr. Hugin is a trustee, but he is not deemed to hold a pecuniary interest in the foundation. Read SEC document
July 31, 2017 Filed Aug 1, 2017 16:52 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	27,443	$0.00 Strike: $135.41	$0.00	Disclosure SEC source: 0001209191-17-046930 · doc4.xml · derivative · entry 6 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,443 Underlying: Common Stock · 27,443 shares Expires 2027-07-31 F4 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F3 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 31, 2018. Read SEC document
July 28, 2017 Filed Aug 1, 2017 16:52 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	44,500	$0.00	$0.00	Disclosure SEC source: 0001209191-17-046930 · doc4.xml · derivative · entry 5 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. F1 · price: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. Read SEC document
July 28, 2017 Filed Aug 1, 2017 16:52 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Tax withholdingCommon Stock	23,073	$134.10	$3,094,089.30	Disclosure SEC source: 0001209191-17-046930 · doc4.xml · nonDerivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 998,086 F2 · shares: This amount reflects shares withheld by the Company for the payment of taxes on the vested shares. Read SEC document
July 28, 2017 Filed Aug 1, 2017 16:52 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	44,500	$0.00	$0.00	Disclosure SEC source: 0001209191-17-046930 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on July 28, 2014 vested and settled for shares of the Company's common stock. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionStock Option (right to buy) · Derivative	2,750	$0.00 Strike: $36.36	$0.00	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · derivative · entry 13 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,750 shares Expires 2022-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015)). F3 · derivative.exercise_date: The option was fully exercisable. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionStock Option (right to buy) · Derivative	55,970	$0.00 Strike: $24.81	$0.00	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · derivative · entry 12 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,970 shares Expires 2018-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The option was issued pursuant to the Company's 1998 Employee Stock Option Plan. F3 · derivative.exercise_date: The option was fully exercisable. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionStock Option (right to buy) · Derivative	60,000	$0.00 Strike: $36.78	$0.00	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · derivative · entry 11 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2017-10-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The option was issued pursuant to the Company's 1998 Employee Stock Option Plan. F3 · derivative.exercise_date: The option was fully exercisable. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionStock Option (right to buy) · Derivative	60,000	$0.00 Strike: $29.27	$0.00	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · derivative · entry 10 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2017-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The option was issued pursuant to the Company's 1998 Employee Stock Option Plan. F3 · derivative.exercise_date: The option was fully exercisable. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	2,750	$36.36	$99,990.00	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · nonDerivative · entry 7 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	SaleCommon Stock	55,970	$134.14	$7,507,815.80	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · nonDerivative · entry 6 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,909 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $134.00 to $135.13, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	55,970	$24.81	$1,388,615.70	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · nonDerivative · entry 5 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	SaleCommon Stock	60,000	$134.14	$8,048,400.00	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · nonDerivative · entry 4 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,909 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $134.00 to $135.13, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	60,000	$33.78	$2,026,800.00	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · nonDerivative · entry 3 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	SaleCommon Stock	60,000	$134.14	$8,048,400.00	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · nonDerivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,909 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $134.00 to $135.13, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document
June 22, 2017 Filed Jun 23, 2017 16:02 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	60,000	$29.26	$1,755,600.00	Disclosure SEC source: 0001209191-17-041629 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 25, 2017 Filed May 30, 2017 19:52 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantStock Option (right-to-buy) · Derivative	8,577	$0.00 Strike: $39.39	$0.00	Disclosure SEC source: 0001179110-17-008221 · edgar.xml · derivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,577 Underlying: Common Stock · 8,577 shares Expires 2017-05-25 F2 · derivative.exercise_date: This option vests in one installment on May 25, 2018 and is made as part of and pursuant to Issuer's director compensation package. Read SEC document
May 25, 2017 Filed May 30, 2017 19:52 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCommon Stock	3,237	$0.00	$0.00	Disclosure SEC source: 0001179110-17-008221 · edgar.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,633 F1 · shares: This restricted stock award vests on May 25, 2018 and is made as part of and pursuant to Issuer's director compensation package. Read SEC document
May 15, 2017 Filed May 17, 2017 21:31 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDirector stock option (right to buy) · Derivative	3,540	$0.00 Strike: $83.28	$0.00	Disclosure SEC source: 0000313616-17-000179 · edgar.xml · derivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,540 Underlying: Common Stock · 3,540 shares Expires 2027-05-15 Read SEC document
May 15, 2017 Filed May 17, 2017 21:31 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	990	$0.00	$0.00	Disclosure SEC source: 0000313616-17-000179 · edgar.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,576 F1 · shares: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date, or the date of (and immediately prior to) the next annual meeting of Danaher's shareholders following the grant date, but the underlying shares are not issued until the earlier of the director's death or the first day of the seventh month following the director's retirement from the Board. Read SEC document
May 01, 2017 Filed May 2, 2017 16:19 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantRestricted Stock Unit · Derivative	13,876	$0.00	$0.00	Disclosure SEC source: 0001209191-17-029187 · doc4.xml · derivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,876 Underlying: Common Stock · 13,876 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.exercise_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. F4 · derivative.expiration_date: The restricted stock units were issued pursuant to the Company's 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) and will vest on May 1, 2020. Vested shares will be delivered to the reporting person on the vesting date. Read SEC document
May 01, 2017 Filed May 2, 2017 16:19 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	27,443	$0.00 Strike: $124.06	$0.00	Disclosure SEC source: 0001209191-17-029187 · doc4.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,443 Underlying: Common Stock · 27,443 shares Expires 2027-05-01 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on May 1, 2018. Read SEC document
April 10, 2017 Filed Apr 12, 2017 16:24 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionStock Option · Derivative	60,000	Not disclosed Strike: $29.02	Not disclosed	Disclosure SEC source: 0001209191-17-026683 · doc4.xml · derivative · entry 4 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2017-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The option was issued pursuant to the Company's 1998 Employee Stock Option Plan. F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document
April 10, 2017 Filed Apr 12, 2017 16:24 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	60,000	$29.02	$1,741,200.00	Disclosure SEC source: 0001209191-17-026683 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 08, 2017 Filed Mar 10, 2017 16:56 UTC	MEDICINES CO /DE MDCO · Entity 152552	Exercise / conversionStock Option (right-to-buy) · Derivative	7,500	Not disclosed Strike: $19.60	Not disclosed	Disclosure SEC source: 0001179110-17-004423 · edgar.xml · derivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2017-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: This option vested in twelve equal monthly installments beginning on June 24, 2007. Read SEC document
March 08, 2017 Filed Mar 10, 2017 16:56 UTC	MEDICINES CO /DE MDCO · Entity 152552	Exercise / conversionCommon Stock	7,500	$19.60	$147,000.00	Disclosure SEC source: 0001179110-17-004423 · edgar.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2017 Filed Feb 16, 2017 17:16 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantPhantom Stock · Derivative	28,510	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-011574 · doc4.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,510 Underlying: Common Stock · 28,510 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock represents a right to receive one share of common stock. F3 · price: The reporting person was awarded 28,510 shares of common stock pursuant to the 2014-2016 Long Term Incentive Plan under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). The reporting person deferred the receipt of such 28,510 shares of common stock and received instead 28,510 shares of phantom stock pursuant to the Celgene Corporation 2005 Deferred Compensation Plan. F2 · derivative.exercise_date: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation. F2 · derivative.expiration_date: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation. Read SEC document
January 30, 2017 Filed Jan 31, 2017 16:21 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	29,669	Not disclosed Strike: $113.18	Not disclosed	Disclosure SEC source: 0001209191-17-006363 · doc4.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,669 Underlying: Common Stock · 29,669 shares Expires 2027-01-30 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on January 30, 2018. F2 · ownership.direct: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). Read SEC document
January 05, 2017 Filed Jan 9, 2017 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionStock Option · Derivative	22,708	Not disclosed Strike: $27.43	Not disclosed	Disclosure SEC source: 0001209191-17-002926 · doc4.xml · derivative · entry 4 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,708 shares Expires 2017-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The option was issued pursuant to the Company's 1998 Employee Stock Option Plan. F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document
January 05, 2017 Filed Jan 9, 2017 16:11 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	22,708	$27.43	$622,766.90	Disclosure SEC source: 0001209191-17-002926 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 913,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 09, 2016 Filed Nov 14, 2016 17:47 UTC	CELGENE CORP /DE/ CELG · Entity 15781	SaleCommon Stock	100,000	$120.00	$12,000,000.00	Disclosure SEC source: 0001209191-16-149843 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 922,201 F1 · price: These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan. Read SEC document
November 09, 2016 Filed Jan 31, 2017 16:22 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GiftCommon Stock	31,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-006364 · doc5.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891,201 F1 · kind: Gift to a family foundation of which Mr. Hugin is a trustee, but he is not deemed to hold a pecuniary interest in the foundation. Read SEC document
October 31, 2016 Filed Nov 2, 2016 16:14 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	29,669	Not disclosed Strike: $102.18	Not disclosed	Disclosure SEC source: 0001209191-16-147898 · doc4.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director · see remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,669 Underlying: Common Stock · 29,669 shares Expires 2026-10-31 F2 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015). F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on October 31, 2017. Read SEC document
July 15, 2016 Filed Jul 19, 2016 20:49 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDirector stock option (right to buy) · Derivative	2,930	$0.00 Strike: $80.92	$0.00	Disclosure SEC source: 0000313616-16-000197 · edgar.xml · derivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,930 Underlying: Common Stock · 2,930 shares Expires 2026-07-15 Read SEC document
July 15, 2016 Filed Jul 19, 2016 20:49 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	970	$0.00	$0.00	Disclosure SEC source: 0000313616-16-000197 · edgar.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970 F1 · security: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date, or the date of (and immediately prior to) the next annual meeting of Danaher's shareholders following the grant date, but the underlying shares are not issued until the earlier of the director's death or the first day of the seventh month following the director's retirement from the Board. Read SEC document
July 15, 2016 Filed Aug 4, 2016 20:03 UTC Amendment	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	970	$0.00	$0.00	Disclosure SEC source: 0000313616-16-000217 · edgar.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,586 F1 · security: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date, or the date of (and immediately prior to) the next annual meeting of Danaher's shareholders following the grant date, but the underlying shares are not issued until the earlier of the director's death or the first day of the seventh month following the director's retirement from the Board. F2 · balance_after: This amendment is being filed to reflect an additional 1,616 shares in Table 1, Column 5, which were inadvertently omitted from the original filing. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.